Gå direkt till huvudinnehållet

Hepatorenalt syndrom

Senast uppdaterad: Publicerad:
Sakkunnig:
  1. Arroyo V, Ginès P, Gerbes A et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76. PubMed  
  2. Rose BD, Runyon BA. Diagnosis and treatment of hepatorenal syndrome. UpToDate, last updated June 13, 2010. UpToDate  
  3. Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105: 229-36. Gastroenterology  
  4. Martin PY, Ginès P, Schrier RW. Role of nitric oxide as mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41. New England Journal of Medicine  
  5. Wiest R, Groszmann RJ. Nitric Oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26. PubMed  
  6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH et al. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-57. PubMed  
  7. Schrier RW, Niederberger M, Weigert A, Ginès P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin Liver Dis 1994; 14: 14-22. PubMed  
  8. Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76. Gastroenterology  
  9. Maroto A, Ginès P, Arroyo V et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17. 788-93.
  10. Guevara M, Bru C, Ginès et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44. PubMed  
  11. Sugano S, Yamamoto K, Atobe T et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients: a placebo, controlled evaluation. J Hepatol 2001; 34: 373-77. PubMed  
  12. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997; 17: 233-48. PubMed  
  13. Follo A, Llovet JM, Navasa M et al. renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501. PubMed  
  14. Sort P, Navasa M, Arroyo V et al. Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-09.
  15. Ginès P, Titó L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1998; 94: 1493-502. Gastroenterology  
  16. Del Olmo JA, Peña A, Serra MA, Wassel AH, Benages A et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000; 32: 19-24. PubMed  
  17. Cárdenas A, Ginès P, Uriz J et al. Renal failure after upper gastrointesinal bleeding in cirrhosis: incidence, clinical course, predicitve factors and short-term prognosis. Hepatology 2001; 34: 671-76. PubMed  
  18. Boyer TD, Zia PKI, Reynolds TB. Effect of indomethacin and prostaglandin A1 in renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77: 215-22. Gastroenterology  
  19. Ginès P, Berl T, Bernardi M et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-64. PubMed  
  20. Gines P, Guevara M, Arroyo V et al. Hepatorenal syndrome. Lancet 2003; 362: 1819-27. PubMed  
  21. Ruiz-Del-Arbol L, Urman J, Fernandez J et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8. PubMed  
  22. Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. J Hepatol 2004; 40: 140-6. PubMed  
  23. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64. PubMed  
  24. Ginès P, Guevara M. Good news for hepatorenal syndrome. Hepatology 2002; 36: 504-06.
  25. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and treatment of hepatorenal syndrome type I with ornipressin and dopamin. Hepatology 1999; 30: 870-75. PubMed  
  26. Ortega R, Ginès P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-48. PubMed  
  27. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30. Gastroenterology  
  28. Uriz J, Ginès P, Cárdenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48. PubMed  
  29. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicenter pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-58. PubMed  
  30. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 HRS with the administration of midodrine and octreotid. Hepatology 1999; 29: 1690-97. PubMed  
  31. Duvoux C, Zanditenas D, Hezode C et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrom: a pilot study. Hepatology 2002; 36; 374-80.
  32. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100: 879. PubMed  
  33. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38: 238-43. PubMed  
  34. Rimola A, Navasa M, Grande L. Liver transplantation in cirrhotic patients with ascites. In Arroyo V, Ginès P, Rodès J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. Malden: Blackwell Science 1999: 492-510.
  35. Arroyo V, Bataller R, Guevara M. Tratment of hepatorenal syndrome in cirrhosis. In Arroyo V, Ginès P, Rodès J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. Malden: Blackwell Science 1999: 492-510.
  36. Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004; 40: 159-61. PubMed  
  37. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-6. PubMed  
  38. Jeyaraja DR, Gonwa TA, McBride M et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64: 1760-65. PubMed  
  39. Gonowa AT, Klintmalm GB, Levy M, Jennings LS, Goldstein RM et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-65. PubMed  
  40. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 1179-85. PubMed  
  41. Guevara M, Ginès P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 27: 35-41. PubMed  
  42. Brensing KA, Textor J, Perz J et al. Long-term outcome after transjugular intrahepatic portosystemic shunt in non-transplant patients with hepatorenal syndrome: a phase II study. Gut 200; 47: 288-95.
  43. Ginès P, Uriz J, Calahorra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albuin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-47. Gastroenterology  
  44. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T et al. Pentoxifyllin improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48. Gastroenterology  
  45. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282. PubMed  
  • Nils Grefberg, med dr och överläkare internmedicin och nefrologi, tidigare vid Medicinkliniken, Centrallasarettet Växjö

Tidigare sakkunniga

  • Bjørnar Grenne, ST-läkare och PhD, Sørlandet Sykehus Arendal
  • Lars Aabakken, försteamanuens vid Universitetet i Oslo, läkare vid medisinsk avdeling, Rikshospitalet